XOMA ROYALTY CORPORATION (XOMA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$40.170.00%
Close 2026-07-14 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · XOMA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Finalize the merger and holding company reorganization with Ligand Pharmaceuticals Incorporated as planned.
Stated as a priority in 3 of last 3 quarters. The merger was consummated on July 14, 2026, completing the acquisition and holding company reorganization. This matches management's stated goal and shows delivery on this strategic priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“On July 14, 2026, the Company consummated the previously announced Merger with Parent.”
“Entered into an Agreement and Plan of Merger with Ligand Pharmaceuticals Incorporated.”
“Announced expected closing of acquisition of XOMA Royalty Holdings Corporation by Ligand Pharmaceuticals.”
Raise full-year royalty revenue guidance reflecting expected growth to $225 million to $250 million.
Stated as a priority in 2 of last 2 quarters. Management raised full-year revenue guidance from $200-$225 million to $225-$250 million. This upward revision aligns with management's stated growth expectations and indicates progress toward higher royalty revenue.
“Royalties are now expected to range from $225 million to $250 million (previously $200 million to $225 million).”
“OJEMDA FY 2026 revenue guidance of $225 – $250 million.”
Raise adjusted earnings per diluted share guidance to a range of $8.50 to $9.50 for fiscal year 2026.
Stated as a priority in 2 of last 2 quarters. Management raised adjusted EPS guidance from $8.00-$9.00 to $8.50-$9.50 for fiscal 2026. Actual diluted EPS in recent quarters ranged from $0.06 to $0.7, indicating early progress but the full-year target remains aspirational.
“Raising adjusted earnings per diluted share guidance to $8.50 to $9.50 (previously $8.00 to $9.00).”
“Adjusted EPS guidance previously set at $8.00 to $9.00 for FY 2026.”
Over the trailing year it converted 0.03x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to real (inflation-adjusted) rates, the US dollar, Fed net liquidity, long-term interest rates (low R² over the window).
23 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.